CEO Remarks

We believe that it is urgent to secure an alternative technology to the current blood transfusion method that heavily relies on blood donation, to strengthen blood supply capabilities in response to deep blood shortages and national disasters, to overcome rare blood supply limitations, and to provide safe blood products without adverse reactions.

In our hands, we can successfully remove antigens that are problematic during transfusion by using gene editing technology to generate artificial red blood cells that can be transfused to anyone. Therefore, we can secure an artificial blood production technology for universal blood transfusion, even for rare blood patients. In addition, by promoting the development of innovative convergence technologies in the advanced regenerative bio field and creating new industries, it is expected to enter the fast-growing alternative artificial blood industry for transfusion and secure competitiveness in the bio-tissue development market such as artificial organs.

We have strong interests not only in the development of human blood substitutes, but also in the development of blood substitutes for companion animals (dogs and cats). Nowadays demand for canine and feline blood products has expanded significantly over the past two decades, due to advances in veterinary medicine and medical care. It is now common for animals to receive blood transfusions for the treatment of several disease processes.

RedGene will continue to pursue the development of human & animal red blood cell substitutes for clinical needs by utilizing competitive research infrastructures, excellent networks, and cutting-edge gene editing & stem cell technologies. We confidently promise that RedGene will successfully achieve the mass-production of artificial red blood cells, non-clinical research to prove efficacy, and obtaining clinical trial approval (IND) as well as active global licensing/partnership deals. Go RedGene! Thanks.



Cheers!

CEO Kaapjoo Park, PhD